Four NovaMedica Executives are in the Top-1000 Russian Managers Rating Released by the Managers Association of Russia and Kommersant Publishing House
03 October 2016
Four NovaMedica executives are among the business leaders listed in the Top-1000 Russian Managers rating released annually by the Managers Association of Russia and Kommersant Publishing House.
NovaMedica Strengthens its Team
27 July 2016
Russian pharmaceutical company NovaMedica announces strengthening of its team. Elena Ilyina formerly holding one of the key positions in Sun Pharma (Ranbaxy) Russia is appointed as Vice President, Business Development.
Photo: Pfizer and NovaMedica announce a strategic partnership in Russia
13 July 2016
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.
Pfizer and NovaMedica announce a strategic partnership in Russia
13 July 2016
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region.
NovaMedica is starting construction of R&D Center for drug development using nanotechnologies
15 December 2015
NovaMedica, a Russian pharmaceutical company, is starting construction of R&D Center for innovative drug development and pilot production in Moscow. This Center will include laboratories and production areas equipped with state-of-the-art process equipment that has never been used in the Russian pharmaceutical industry before. The total investments are estimated approximately $15 million.
NovaMedica is sharing knowledge
29 September 2015
NovaMedica actively involved in RNOF-2015 (Russian National Ophthalmological Forum) that took place in Moscow, September 23, 2015. This is one of the most important educational events in ophthalmology.
22 September 2015
September 17, 2015, Moscow held IBD School (Inflammatory Bowel Disorder School) chaired by the head gastroenterologist of the Moscow Region, Professor Elena Belousova. NovaMedica was the general partner of this educational event that brought together over 100 gastroenterologists from Moscow and other regions of Russia.
NovaMedica opens the program of scientific-practical events for Russian gastroenterologists
16 July 2015
Russian pharmaceutical company NovaMedica takes an active part in the V Baikal Forum on Inflammatory Bowel Diseases (IBD), which befalls from 16 to 18 of July in Irkutsk. Participating in this event NovaMedica opens a series of scientific and practical programs for the professional community of gastroenterologists.
Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions
22 June 2015
June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty.
NovaMedica is planning to create around 15 innovative nanotech-involved pharmaceutical products
18 June 2015
A Russian pharmaceutical company NovaMedica is planning to grow its R&D activities targeted at building a portfolio of proprietary nanotech-involving pharmaceutical products. This is what has been announced today by Vladimir Gurdus, General Manager at RMI Partners, managing company of NovaMedicw, at the Annual Saint Petersburg International Economic Forum during his panel discussion titled “Nanotechnologies – meeting the expectations?”
NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
21 March 2023
Merry Christmas and Happy New Year!
27 December 2022
NovaMedica registers two own-development CNS products, one without equivalents in Russia and the other – in the world
15 December 2022
4 Key Priorities for the European Medicines Agency in 2023
02 June 2023
CRISPR-based microbial gene therapy delivers promise
02 June 2023
FDA Releases Final Guidance on Adjusting for Covariates in Randomized Clinical Trials
01 June 2023
Small biotech turns CRISPR against bacteria, reducing E. coli in small early study
01 June 2023